首页> 外文期刊>International Journal of Pharmacy and Pharmaceutical Sciences >FORMULATION DEVELOPMENT AND EVALUATION OF GASTRO-RETENTIVE DOSAGE FORM OF ATAZANAVIR SULPHATE
【24h】

FORMULATION DEVELOPMENT AND EVALUATION OF GASTRO-RETENTIVE DOSAGE FORM OF ATAZANAVIR SULPHATE

机译:阿扎那韦硫酸盐的胃滞留剂型的配方开发与评价

获取原文
           

摘要

Objective: To improve dissolution properties of atazanavir sulphate by preparing gastro-retentive granules by solid dispersion method and development of RP-HPLC method for estimation of this drug. Methods: Estimation of atazanavir sulphate was done using high performance liquid chromatography (HPLC) on inertsil column (5 μm, 250x4, 6 mm) with a mobile phase consists of methanol: water (91:9 v/v), at 0.5 ml/min flow rate and 249 nm UV detection. The method was validated as per ICH guidelines. Selection of the carrier for gastro-retentive formulation was based on phase solubility study of the drug. Solid dispersions of gastro-retentive granules of different composition of drug and carrier, were prepared by the kneading, heating and solvent evaporation. A 3 2 factorial design was applied to optimize the gastro-retentive formulation. The amounts of polyethylene glycol 6000 (PEG 6000) (X1) and hydroxypropyl methyl cellulose (HPMC) (X2) were selected as independent variables and in vitro -release at 5, 9 h and total floating time was selected as dependent variables. Results: HPLC method was found to be linear in a concentration range of 10-60 μg/ml of the drug (r 2 = 0.999). The low value of % RSD in precision study indicates reproducibility of the method. The low value of LOD and LOQ suggests the sensitivity of the method. The solubility enhancement study of drug with various carriers followed descending order of solubility [Gelucire 44/14>PEG 6000>polyvinyl pyrrilidone (PVP)]. Highest % cumulative release was observed for the heating method at drug polymer (PEG 6000) ratio 1:5. Hence, this ratio has been selected for preparation of solid dispersion. From comparison of dissolution profile of formulated batches, formulation F4 [containing PEG6000 (1.6 g) and HPMC (200 mg)] showed promising dissolution parameters with desired floating properties. Conclusion: Results obtained by validation studies suggested that the developed HPLC method is simple, accurate, precise and can be used for routine analysis of atazanavir sulphate formulation. Results of evaluation of prepared batches indicate that batch F4 is a promising formulation for gastro-retentive dosage form of drug.
机译:目的:通过固相分散法制备胃滞留颗粒,改善阿扎那韦硫酸盐的溶出特性,并开发RP-HPLC法对该药物进行评价。方法:使用高效液相色谱(HPLC)在inertsil色谱柱(5μm,250x4,6 mm)上以0.5 ml / ml的甲醇:水(91:9 v / v)组成的流动相对硫酸阿扎那韦进行估算最小流速和249 nm紫外线检测。该方法已按照ICH指南进行了验证。用于胃滞留制剂的载体的选择基于药物的相溶性研究。通过捏合,加热和溶剂蒸发来制备不同药物和载体组成的胃滞留颗粒的固体分散体。应用3 2阶乘设计来优化胃滞留配方。选择聚乙二醇6000(PEG 6000)(X1)和羟丙基甲基纤维素(HPMC)(X2)的量作为自变量,并选择5、9 h的体外释放量和总漂浮时间作为因变量。结果:发现HPLC方法在10-60μg/ ml药物浓度范围内是线性的(r 2 = 0.999)。精密度研究中%RSD的值较低,表明该方法具有可重复性。 LOD和LOQ的低值表明该方法的灵敏度。各种载体对药物的溶解度增强研究遵循溶解度降序[Gelucire 44/14> PEG 6000>聚乙烯吡咯烷酮(PVP)]。对于加热方法,在药物聚合物(PEG 6000)比例为1:5的情况下,观察到最高的累积释放百分比。因此,选择该比例用于制备固体分散体。通过比较配制批次的溶出曲线,配方F4 [包含PEG6000(1.6 g)和HPMC(200 mg)]显示了具有希望的漂浮特性的有希望的溶出参数。结论:通过验证研究获得的结果表明,所开发的HPLC方法简单,准确,精确,可用于硫酸阿扎那韦制剂的常规分析。制备批次的评估结果表明,批次F4是有希望的药物用于胃滞留剂型的制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号